Search tips
Search criteria 


Logo of oncotargetLink to Publisher's site
Oncotarget. 2016 September 20; 7(38): 61312–61324.
Published online 2016 August 2. doi:  10.18632/oncotarget.11016
PMCID: PMC5308653

miR-450b-5p induced by oncogenic KRAS is required for colorectal cancer progression


The development and progression of CRC are regarded as a complicated network and progressive event including genetic and/or epigenetic alterations. Recent researches revealed that MicroRNAs are biomarkers and regulators of CRC progression. Analyses of published microarray datasets revealed that miR-450b-5p was highly up-regulated in CRC tissues. In addition, high expression of miR-450b-5p was significantly associated with KRAS mutation. However, the role of miR-450b-5p in the progression of CRC remains unknown. Here, we sought to validate the expression of miR-450b-5p in CRC tissues and investigate the role and underlying mechanism of miR-450b-5p in the progression of CRC. The results revealed that miR-450b-5p was up-regulated in CRC tissues, high expression level of miR-450b-5p was positively associated with poor differentiation, advanced TNM classification and poor prognosis. Moreover, miR-450b-5p was especially high in KRAS-mutated cell lines and could be up-regulated by KRAS/AP-1 signaling. Functional validation revealed that overexpression of miR-450b-5p promoted cell proliferation and tumor growth while inhibited apoptosis of CRC cells. Furthermore, we demonstrated that miR-450b-5p directly bound the 3′-UTRs of SFRP2 and SIAH1, and activated Wnt/β-Catenin signaling. In conclusion, miR-450b-5p induced by oncogenic KRAS is required for colorectal cancer progression. Collectively, our work helped to understand the precise role of miR-450b-5p in the progression of CRC, and might promote the development of new therapeutic strategies against CRC.

Keywords: miR-450b-5p, Wnt/β-Catenin pathway, colorectal cancer, progression, KRAS


Colorectal cancer (CRC) is one of the most commonly digestive malignant tumor worldwide and the incidence of which increases rapidly among different kinds of cancer in recent decades [1]. Although survival rates of CRC patients with early stage disease have improved in the last few years, the clinical outcome of CRC patients with advanced stage disease still remains poor [1, 2]. Therefore, there is a pressing need for more effective treatment options.

The development and progression of the most sporadic CRC follow the classical adenoma-carcinoma sequence which is a result of the accumulation of genetic mutations and epigenetic alterations [3]. Mutations on tumor suppressor adenomatous polyposis coli (APC), KRAS, BRAF, or TP53 genes have been characterized as key factors of CRC cancer-initiating [35]. Deletion or mutations in APC or stabilizing mutations in β-Catenin lead to intracellular β-Catenin accumulation and constitutively activate the Wnt/β-Catenin signaling [6, 7], which in turn stimulates the expression of a number of target genes that drive tumorigenesis [8, 9].

Activation of the Wnt signaling pathway caused by mutations in these genes has been seen in over 85% of sporadic CRC patients [10]. However, it is interesting that heterogeneous activation of Wnt/b-catenin signaling exists in individual CRC tumors. Nuclear accumulation of b-Catenin, one of the hallmarks of Wnt/β-catenin activation, significantly increased in those dedifferentiated tumor cells at the edge of CRC tissues. In contrast, less intracellular accumulation of β-Catenin was observed in the central areas of tumor masses [11, 12]. This kind of dynamic status of Wnt/β-catenin signaling can be difficultly explained simply by genetic mutations in APC or β-Catenin in CRC. Actually, alternative regulations of Wnt/β-Catenin signaling in CRC cells with mutations in APC or β-Catenin have been identified. For example, Wnt/β-Catenin activity induced by mutant APC or β-Catenin can be partially inhibited by upstream secreted Frizzled-related proteins (SFRPs) [13], and overexpression of Axin can down-regulate β-Catenin in APC-mutated CRC cells [14]. In addition, the ubiquitin proteasome degradation is a main regulatory pathway for β-catenin. SIAH1 binds with the carboxyl end of APC and promotes the degradation of β-catenin [15, 16]. These researches suggest that Wnt/β-catenin signaling can be activated or inhibited at many levels with a wide and dynamic range.

MicroRNAs (miRNAs) are a class of highly conserved single-stranded noncoding RNAs that regulate protein expression at the posttranslational level through binding to the 3′-untranslated region (UTR) of their target mRNAs [17, 18]. Recent researches have revealed that miRNAs are biomarkers and regulators of CRC progression [19]. Additionally, a small group of miRNAs has been proved to be involved in tumorigenesis or progression of CRC through modulation of Wnt/β-Catenin signaling pathways [2025].

Recently, miR-450b-5p has been shown to be associated with proliferation, differentiation as well as chemo-resistance of some cancer cells [26, 27], and our preliminary work and published microarray analysis also indicated that the expression of miR-450b-5p was up-regulated, and it can induce activation of Wnt/β-Catenin signaling in CRC. But the role of miR-450b-5p in CRC progression and the molecular mechanisms about regulating the activation of Wnt/β-Catenin signaling are unclear.

Herein, our study suggested that miR-450b-5p induced by KRAS took part in the progression of CRC cells with mutations in APC or β-Catenin, and high expression level is associated with aggressive phenotype and poor prognosis of patients with CRC. Further investigations revealed that miR-450b-5p directly bound the 3′-UTRs of SFRP2 and SIAH1, which function as regulators of Wnt/β-Catenin signaling, boosting the activation of Wnt/β-Catenin signaling, and promoting the progression of CRC.


Overexpression of miR-450b-5p correlates with CRC progression

Several published CRC miRNA microarray datasets showed that miR-450 was among the highest microRNAs in CRC tissues [28]. Analyses of GEO ( CRC miRNA microarray datasets also revealed that miR-450b-5p was markedly overexpressed in primary CRC tissues as compared with normal colon tissues (Supplementary Figure S1, NCBI/GEO/GSE46622 and GSE28364; n=16 and n=80). We then validated the expression of miR-450b-5p in human CRC tissues samples. In agreement with the analytical results from the published CRC miRNA microarray datasets, our analysis also uncovered that miR-450b-5p was dramatically overexpressed in 170 primary CRC tissues compared with 10 normal colon tissues (Figure (Figure1A1A).

Figure 1
Overexpression of miR-miR-450b-5p correlates with CRC progression

Next, we explore the clinicopathological significance of miR-450b-5p. The results indicated that high expression of miR-450b-5p was positively associated with advanced TNM stage in patients with CRC (Figure 1B-1D, Supplementary Table S1 and S2). According to the median ratio (5.84) of relative miR-450b-5p expression, the 170 samples were classified into two groups: the high-miR-450b-5p group (n=85, miR-450b-5p expression ratio> median ratio), and the low-miR-450b-5p group (n=85, miR-450b-5p expression ratio<mean ratio). The survival analysis indicated that the group of high miR-450b-5p expression had shorter 5-year overall survival and 5-year disease-free survival (Figure (Figure1E,1E, log-rank, P<0.001), and the benefit for survival from low miR-450b-5p expression is an independent effect for patients with CRC (Supplementary Table S3).

KRAS signaling enhances miR-450b-5p expression in CRC

When the expression of miR-450b-5p in CRC was analyzed using published miRNA microarray datasets (NCBI/GEO/GSE28364; n=80), an interesting result was found that the miR-450b-5p was significantly higher in KRAS mutant CRC samples than that in KRAS wild CRC samples (Supplementary Figure S2, P<001, n=40), which was proved by Q-PCR in CRC tissue samples (Figure (Figure2A,2A, P<001, n=83). Moreover, we detected the expression of miR-450b-5p in KRAS wild and KRAS mutant CRC cell lines, the results suggested that the expression of miR-450b-5p in CRC cell lines with KRAS mutation (HCT116, SW2620 and SW480) was much higher than that in cell lines with wild type KRAS (HT29, Caco2 and COLO250) (Figure (Figure2B,2B, P<0.01), and there was no significant correlation between the expression level of miR-450b-5p and the type of KRAS mutation (Supplementary Figure S3). Meanwhile, the expression of miR-450b-5p was obviously increased in the KRAS wild CRC cells with mutant KRASG12D transduction (Figure (Figure2C,2C, P<0.01), whereas it was decreased in the KRAS mutant CRC cells treated with KRASG12D-siRNA (Figure (Figure2D,2D, P<0.01). These results indicated that miR-450b-5p might be up-regulated upon KRAS mutation in CRC cells.

Figure 2
KRAS signaling enhances miR-450b-5p expression in CRC

We next investigated the potential molecular mechanism through which KRAS may up-regulate miR-450b-5p. Bioinformatics' analysis revealed a putative c-FOS binding site in the promoter of miR-450b-5p gene at −151 to −200 bp. C-FOS is key member of the transcription factor AP-1, which is a well-known downstream gene of KRAS signaling. We then tested whether c-FOS could bind with the promoter of miR-450b-5p by ChIP assay using seven pairs of primers covering −1000 to +1 bp of miR-450b-5p promoter. The results indicated a putative 50 bp fragment in miR-450b-5p promoter (−200 to −151) as a potential binding region of miR-450b-5p, which contains the predictive binding site (Figure (Figure2E).2E). Further luciferase reporter assay showed that the predictive site −200bp to −151bp in miR-450b-5p promoter bound with AP-1, whereas the mutants of bp −200 to −150 showed no binding with AP-1 (Figure (Figure2F).2F). Moreover, the expression of miR-450b-5p was coordinated with c-FOS (Figure 2B-2D, Supplementary Figure S4). These results indicate that AP-1 could up-regulate miR-450b-5p through direct binding with the promoter of miR-450b-5p.

miR-450b-5p promotes CRC progression in vitro and in vivo

We explore the function of miR-450b-5p over-expression in CRC progression. Over-expression of miR-450b-5p obviously accelerated, whereas inhibition of miR-450b-5p decreased, growth rate, anchorage-independent growth and proliferation index (calculated by Ki-67 expression) ability of CRC cells (Figure 3A-3C, Supplementary Figure S5A-S5C). Meanwhile, the stimulatory effect of miR-450b-5p on apoptosis was analyzed. The results showed that overexpression of miR-450b-5p obviously reduced, whereas inhibition of miR-450b-5p increased, apoptosis rate of CRC cells (Figure 3D-3E, Supplementary Figure S5D-5E and Supplementary Figure S6).

Figure 3
miR-450b-5p promotes CRC aggressiveness in vitro and in vivo

We also engineered SW480 cells to stably express miR-450b-5p and miR-450b-5p-inhibitor, and then the engineered CRC cells were injected into the dorsal flank of nude mice. The results showed the tumors from miR-450b-5p-overexpressing SW480 cells were much larger, whereas formed by miR-450b-5p-inhibited cells were smaller. Meanwhile, miR-450b-5p-overexpressing tumors showed an increased proliferation index and decreased apoptotic rate (Figure 3F-3H, Supplementary Figure S5F-5H), whereas miR-450b-5p-inhibited tumors displayed a lower proliferation index and a higher apoptotic rate (Figure (Figure3G3G and Supplementary Figure S5G). These results demonstrate that miR-450b-5p overexpression promotes CRC tumor growth in vivo.

miR-450b-5p activates Wnt signaling pathway in CRC

Bioinformatics analysis of these genes revealed many biological processes and pathways that were potentially involved in the progression of CRC, including the GO terms proteolysis, apoptosis, notably the KEGG pathways Wnt signaling pathway and ubiquitin mediated proteolysis (Figure (Figure4A4A).

Figure 4
miR-450b-5p activates Wnt signaling pathway in CRC

Next, the effect of miR-450b-5p on location of β-catenin and activity of Wnt/β-Catenin signaling were analyzed. The results of the Wnt signaling luciferase reporter assay showed that ectopic expression of miR-450b-5p remarkably increased the luciferase activity, while inhibition of miR-450b-5p repressed the luciferase activity (Figure (Figure4B).4B). In addition, miR-450b-5p increased the β-catenin expression level both in cytoplasm and in nuclear (Figure (Figure4C,4C, Supplementary Figure S7). Moreover, the expression of Wnt signaling downstream genes was also analyzed. The results showed that ectopically expressing of miR-450b-5p significantly increased the expression of Cyclin D1 but decreased the expression of P21 and P27; instead, overexpression of miR-450b-5p-inhibitor remarkably decreased the expression of Cyclin D1 but increased the expression of P21 and P27 (Figure 4D, 4E).

miR-450b-5p directly binds the 3′-UTRs of SIAH1 and SFRP2 and inhibits their expression

On analyzing the predicted targets using public algorithms (TargetScan and miRANDA), we noticed that SIAH1 and SFRP2 might be key targets of miR-450b-5p that might involve in regulation of Wnt signaling (Figure (Figure5A).5A). We then validated the effect of miR-450b-5p on SIAH1and SFRP2 expression. The results showed that miR-450b-5p decreased the expression, whereas miR-450b-5p inhibitor increased the expression of SIAH1and SFRP2 at both transcriptional and translational levels (Figure 5B and 5C). When tested using the dual luciferase reporter vectors containing a complete wild-type SIAH1-3′-UTR and SFRP2-3′-UTR, miR-450b-5p inhibited the expression of GFP, but not the control in CRC SW480 cells (Figure (Figure5D).5D). Furthermore, the luciferase reporter assay also demonstrate that over-expression of miR-450b-5p dramatically inhibited the luciferase activity of the wild SIAH1-3′-UTR and SFRP2-3′UTR in a dose-dependent manner, and ectopic expression of miR-450b-5p had no the same effect on the mutant SIAH1-3′-UTR and SFRP2-3′ UTR (Figure (Figure5E5E).

Figure 5
miR-450b-5p directly targets SIAH1 and SFRP2

Repression of SIAH1 and SFRP2 inhibits the CRC progression induced by miR-450b-5p

To further confirm the role of miR-450b-5p in the progression of CRC, SIAH1 and SFRP2 ORF constructs without 3′UTRs were transfected in SW480 cells with miR-450b-5p overexpressing (Figure (Figure6A),6A), and their effects on growth and apoptotic rate were detected. The restoration experiment indicated that re-expression of SIAH1 or/and SFRP2 decreased the growth rate of SW480 cell (Figure (Figure6B).6B). However, the re-expression of SIAH1 or/and SFRP2 increased apoptotic rate of SW480 cell (Figure (Figure6C6C).

Figure 6
Repression of SIAH1 and SFRP2 inhibits the CRC progression induced by miR-450b-5p, and the clinical relevance of miR-450b-5p and its targets in CRC

Then the correlation between the expression of miR-450b-5p and the expression of SIAH1 and SFRP2 was analyzed in 10 freshly CRC tissues. The results indicated that the expression of miR-450b-5p negatively correlated with the expressions of SIAH1 (Figure (Figure6D,6D, r=−0.755, P<0.001) and SFRP2 (Figure (Figure6E,6E, r=−0.791, P<0.001).

Taken altogether, the above results revealed that AP-1, a downstream gene of KRAS signaling, up-regulates the expression of miR-450b-5p, which activates Wnt signaling and inhibits apoptosis by decreasing the expression of SIAH1 and SFRP2, resulting in CRC progression (Figure (Figure6G6G).


Activation of the KRAS and Wnt signaling pathways are two key genetic events underlying the development of CRC. The two pathways can cooperate to promote the progression of CRC. Some studies have previously shown that oncogenic KRAS signaling promotes the Wnt/β-catenin pathway through LRP6 and GSK-3β in CRC [29, 30]. Moreover, it is well known that microRNAs inhibit genes expression and pathways crosstalk, and increasing researches indicate that microRNAs participate in the progression of many kinds of human malignant cancers [31, 32]. However, the function of microRNAs for the KRAS and Wnt signaling pathways interaction in CRC still remains puzzling. Herein, we demonstrate that miR-450b-5p up-regulated by KRAS activate Wnt/β-Catenin signaling in CRC cells.

So far, there has been little discussion about the function of miR-450b in pathogenesis of cancer. Recent studies have shown that miR-450b functions as a new tumor repressor, suppressing the proliferation of tumor cells in breast cancer and rhabdomyosarcoma [26, 33], and miR-450b-5p inhibits stemness and the development of chemoresistance in CRC [27, 34]. However, our results and published microarray analysis [35, 36] showed that the miR-450b-5p expression was up-regulated in CRC, and was associated with aggressive phenotype and poor patient prognosis. Moreover, ove-rexpression of miR-450b-5p significantly promoted, whereas inhibition of miR-450b-5p impaired, CRC cell growth rate in vitro and vivo. Therefore, these results show that miR-450b-5p may serve as an oncogene in CRC progression. These opposite effect of miR-450b-5p on tumorigenesis in different cancers may lie in the different cell types and its target genes (different genes activated in different stages of the cancer progression) [37] [38].

Over the past decade, Wnt/β-Catenin signaling is considered as a hallmark of colorectal tumorigenesis [3941]. Our results show that miR-450b-5p activates Wnt/β-Catenin signaling by directly binding the 3′-UTRs of SIAH1. SIAH1 has emerged as a tumor suppressor, inhibits cell proliferation and promotes apoptosis, by binding with APC and promoting the degradation of β-catenin [16, 42]. Moreover, our results also suggest that miR-450b-5p activates Wnt/β-Catenin signaling by decreasing the expression SFRP2, another negative modulator of Wnt pathway, and its expression can be inhibited by methylation and microRNAs in CRC and other malignant cancers [4345]. We restored the expression of SIAH1 and SFRP2 in miR-450b-5p-overexpressing CRC cells, which showed that overexpression of SIAH1 and SFRP2 remarkably reduced the cells growth rate, and promoted apoptosis. Taken together, miR-450b-5p promotes CRC progression through activation of Wnt/β-Catenin signaling by decreasing the expression of SIAH1 and SFRP2.

MiR-450b-5p expression was up-regulated in CRC; however, how miR-450b-5p was up-regulated in tumor cells still remains unknown. Analyzing the expression of miR-450b-5p in CRC, we also noticed that the miR-450b-5p was dramatically higher in KRAS wild CRC samples than that in KRAS mutant CRC samples. Therefore, we speculated that KRAS activating mutations may increase the expression of miR-450b-5p in CRC. KRAS is an important and frequently mutated gene during CRC progression [46, 47], and its activating mutations result in CRC cells proliferation, invasion and metastasis [4850].

The transcription factor AP-1 is a downstream gene of KRAS signaling. Some reports have implicated that c-FOS (a member of the transcription factor AP-1 component) plays an important role in the tumorigenesis of several human cancers. For example, it has been reported that knockdown of c-FOS suppresses the growth of CRC cells in nude mice [51], and c-FOS interacting with other proteins enhances the transcription of IL-6 and VEGF-A, and promotes angiogenesis in CRC [52]. Our present study showed that miR-450b-5p in CRC cells was up-regulated by direct binding of c-FOS to the promoter region of miR-450b-5p gene to initiate its transcription. This reveals a mechanistic basis for miR-450b-5p overexpression in CRC cells. Thus, disruption of KRAS/AP-1-induced miR-450b-5p expression may contribute to the development of anti-CRC therapy.

In conclusion, we demonstrate that miR-450b-5p induced by oncogenic KRAS is required for colorectal cancer progression. Understanding the precise function of miR-450b-5p in the development of CRC and the specific molecular mechanism of the Wnt/β-Catenin pathway activation will enriching our knowledge about CRC progression, and may provide theoretical evidence for individualized treatment and development of molecule-targeting agents of CRC.


Clinical specimen

The clinical research of samples was performed according to the written approval obtained from the Southern Medical University Institutional Board (Guangzhou, China). All the specimens were collected with informed consent of patients. CRC tissue samples (n=170) were collected between 2008 and 2010, and 50 CRC tissues and the matched adjacent normal tissues were obtained between 2014 and 2015 at the Department of Pathology, Southern Medical University. Surgically resected tissues were frozen in liquid nitrogen immediately until future analysis. The medical records of patients were reviewed for acquisition of the clinicopathological information: age, gender, differentiation, and TNM stage. Survival data were available for the cohort of 170 patients. The median follow-up time was 23 (range, 1-59.6) months.

Cell culture

Human CRC cell lines were purchased from The Global Bioresource Center (ATCC, USA). COLO205 was cultured in RPMI 1640 medium (Gibco, Grand Island, NY, USA) containing 10% fetal bovine serum (Gibico, Grand Island, NY, USA); SW620 and SW480 cells were cultured in Leibovitz's L-15 Medium supplemented with 10% FBS (Gibico); HT29, HCT116 cells were cultured in McCoy's 5a Medium Modified with 10% FBS (Gibico); Caco-2 cell was cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco) with 10% FBS (Gibico). All the cells were cultured at 37°C, 5% CO2.

Real-time PCR

The total miRNA was extracted from tissues or cells using mirVana miRNA Isolation Kit (Ambion, Austin, TX, USA) following the manufacturer's instructions. After that, cDNA was generated from total miRNA using the Tapman miRNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). Real-time quantitative PCR was performed using the Applied Biosystems 7500 sequence detection system iQTM SYBR Green Supermix (BioRad Laboratories, Hercules, CA, USA) containing 5ng cDNA and 10pM of each primer, under the cycling conditions: 5min at 94°C, 40 cycles (30s at 95°C, 30s at 56°C). The expression of mir-450b was measured using Ct (threshold cycling) value and its relative quantification was calculated by normalizing with U6 (internal control of small nuclear RNA expression) as 2−[(CT of mir-450b-5p)-(CT of U6)]. For quantification of other genes, RT-qPCR was performed as described preciously [31]. The primers used are listed in Supplementary Table S4.

Western blotting

Proteins were isolated, subjected to SDS-page, transferred onto PVDF membranes and incubated with antibodies anti-SIAH1 (Abcam, Cambridge, MA, USA), anti-SFRP2 (Cell Signaling Technology, Danvers, MA, USA), anti-KRAS (Proteintech, USA), anti-Ki-67 (Abcam, Cambridge, MA, USA), anti-p27, anti-p21, anti-cyclinD1 (Bioworld Technology Inc. St. Louis Park, MN, USA). LamB1 and a-tubulin (Sigma, Saint Louis, MO, USA) were used as loading controls. Then, the membranes were detected by chemiluminescence. All operations above were performed in accordance with standard methods.

Plasmids and transfection

To construct the plasmid that overexpresses mir-450b-5p, a 78bp fragment of pri-mir-450b-5p was PCR-amplified, then generated into the lentiviral vector pLVTHM (Addgene Inc., Cambridge, MA, USA). The mimics, negative control and inhibitor of mir-450b-5p were purchased from Genecopoeia (Guangzhou, Guangdong, China), and transfected into cells with Lipofectamine 2000 reagent (Invitrogene), according to the manufacturer's instruction. For luciferase assay, small regions containing the target sequences of mir-450b-5p in target genes 3′-UTR were generated by PCR amplification and cloned into pGL3-basic luciferase reporter plasmid (Promega). Two concentrations of mir-450b-5p mimics or inhibitors (20 and 50 nM) were applied. The primers are listed in Supplementary Table S5.

MTT assay, colony formation assay, soft-agar colony formation assay, flow cytometry assay, luciferase assay

The mimics, inhibitor, and negative control oligos of mir-450b-5p were transfected into cells for MTT assay, colony formation assay, soft-agar colony formation assay, flow cytometry assay and luciferase assay. For details, please see supplementary materials.

Terminal transferase dUTP nick end labeling (TUNEL) assay

The TUNEL assay was used to detect DNA degradation of nuclear chromatin in apoptotic cells, according to the manufacturer's instructions (Promega, USA). In brief, 5×104 cells were seeded on glass coverslips in 24-well plates, cultured for 24 h. Then these cells were treated with doxorubicin (1.0μM) for 12 h and mir-450b-5p mimics or inhibitor oligos were transiently transfected into these cells. After transfection for 24 h, these cells were fixed by paraffin for 1 h, followed by 0.1 % Triton X-100 in phosphate buffered saline (PBS) for 15 min at room temperature (RT). After washing with PBS for 3 min, the slides were incubated with 20μg/ml proteinase K for 20 min at room temperature. The slides were then washed with 1 × PBS and incubated with 1×TdT buffer for approximately 30 min at room temperature. Subsequently, the slides were incubated with 57 μl of mix buffer and 3μl of TdT enzyme for 60 min at 37°C. After being washed three times with PBS, flow cytometry was used to analyze the prepared cells.

Chromatin immunoprecipitation (CHIP) assay

According to the manufacturer's instructions (Thermo Fisher, USA), cells were seeded in plates for 24 h, and formaldehyde was added drop-wise to the dishes to a final concentration of 0.75% for cross-linking the protein and DNA at RT for 10 min. Glycine was added to a final concentration of 125 mM and the dishes were shaken at RT for 5 min. The cells were then harvested in cold PBS. After centrifugation for 5 min, the supernatant was discarded and the cell pellets were resuspended in the lysis buffer. After sonicating, lysate was centrifuged and the supernatant was immunoprecipitated using a mouse anti-AP-1 antibody (Abcam, Cambridge, MA, USA) or a rabbit polyclonal antibody (Cell Signaling Technology, Danvers, MA, USA) overnight at 4°C. Seven pairs of primers used for qPCR analysis were listed in Supplementary table S6.

Xenograft model in nude mice

For tumorigenesis assays, stable cell lines were established by a lentiviral-based system (pLVTHM) including miR-450b-5p, miR-450b-5p-inhibitor and negative control. To generate xenograft tumors, the above-mentioned cells (2×106 for each cell line) were subcutaneous injected on the hind limbs of 4-6-week-old female Balb/C athymic mice(nu/nu; Animal Center of Southern Medical University, Guangzhou, China; n=6 for each group). All the mice were housed and maintained under specific pathogen-free conditions, and all operations in experiments were in conformity with institutional guidelines and approved by the Use Committee for Animal Care. Tumor size was measured by a slide caliper, and tumor volume was determined by the formula: 0.44×A×B2 (A for diameter of the base of tumor, and B for corresponding perpendicular value). Tumors removed from mice were fixed in formalin (neutral buffered 10%), embedded in paraffin, and prepared into 4μm sections for staining with haematoxylin.

Statistical analysis

Data were analyzed using SPSS 19.0 for Windows. The Mann-Whitney U-test and Spearman's correlation analyses were applied for analyzing the relationship between the expression of mir-450b-5p and clinicopathological features of CRC cases. The two-tailed paired Student's t-test was used for comparing two experiment groups. 5-year-overall-survival and disease-free survival curves were plotted by the Kaplan-Meier method and compared with the log-rank test. COX's proportional hazard regression model was established for multivariate analysis of the combinational contribution of mir-450b-5p and clinicopathological features to the survival of patients. P<0.05 was considered significant.

Accession numbers for data sets

The different expression of mir-450b-5p generated in the study came from the GEO database (GSE46622 and GSE28364), The expression of mir-450b-5p in different KRAS genotype reanalyzed in the study came from the GEO database (GSE28364).



This work was supported by the National Basic Research Program of China (973 program, 2015CB554002), Project of the National Natural Science Foundation of china supported by NSFC-Guangdong Joint Fund (U1201226), the National Natural Science Foundation of China (81472313, 81172055, and 81472710, 81402277), Guangdong Provincial Natural Science Foundation of China (S2012010009643, 2014A030313283, 2016A030310395, 2016A030310392), the Science and Technology Innovation Foundation of Guangdong Higher Education (CXZD1016) and the Key Program of the National Natural Science Foundation of Guangdong (2010B031500012), Guangzhou Science & Technology Plan Project (201300000056).



No potential conflicts of interest were disclosed.


1. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383:1490–502. doi: 10.1016/s0140-6736(13)61649-9. [PubMed] [Cross Ref]
2. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW. Colorectal cancer. Lancet. 2005;365:153–65. doi: 10.1016/s0140-6736(05)17706-x. [PubMed] [Cross Ref]
3. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med. 2009;361:2449–60. doi: 10.1056/NEJMra0804588. [PMC free article] [PubMed] [Cross Ref]
4. Pritchard CC, Grady WM. Colorectal cancer molecular biology moves into clinical practice. Gut. 2011;60:116–29. doi: 10.1136/gut.2009.206250. [PMC free article] [PubMed] [Cross Ref]
5. Suraweera N, Robinson J, Volikos E, Guenther T, Talbot I, Tomlinson I, Silver A. Mutations within Wnt pathway genes in sporadic colorectal cancers and cell lines. Int J Cancer. 2006;119:1837–42. doi: 10.1002/ijc.22046. [PubMed] [Cross Ref]
6. Yang J, Zhang W, Evans PM, Chen X, He X, Liu C. Adenomatous polyposis coli (APC) differentially regulates beta-catenin phosphorylation and ubiquitination in colon cancer cells. J Biol Chem. 2006;281:17751–7. doi: 10.1074/jbc.M600831200. [PubMed] [Cross Ref]
7. Fodde R, Smits R, Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer. 2001;1:55–67. doi: 10.1038/35094067. [PubMed] [Cross Ref]
8. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–67. [PubMed]
9. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996;87:159–70. [PubMed]
10. Robbins DH, Itzkowitz SH. The molecular and genetic basis of colon cancer. Med Clin North Am. 2002;86:1467–95. [PubMed]
11. Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-Schughart LA, Knuechel R, Kirchner T. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A. 2001;98:10356–61. doi: 10.1073/pnas.171610498. [PubMed] [Cross Ref]
12. Brabletz T, Jung A, Hermann K, Gunther K, Hohenberger W, Kirchner T. Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol Res Pract. 1998;194:701–4. [PubMed]
13. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD, Pretlow TP, Yang B, Akiyama Y, Van Engeland M, Toyota M, Tokino T, Hinoda Y, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet. 2004;36:417–22. doi: 10.1038/ng1330. [PubMed] [Cross Ref]
14. Hart MJ, de los Santos R, Albert IN, Rubinfeld B, Polakis P. Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. Curr Biol. 1998;8:573–81. [PubMed]
15. Liu J, Stevens J, Rote CA, Yost HJ, Hu Y, Neufeld KL, White RL, Matsunami N. Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol Cell. 2001;7:927–36. [PubMed]
16. Leung CO, Deng W, Ye TM, Ngan HY, Tsao SW, Cheung AN, Pang RT, Yeung WS. miR-135a leads to cervical cancer cell transformation through regulation of beta-catenin via a SIAH1-dependent ubiquitin proteosomal pathway. Carcinogenesis. 2014;35:1931–40. doi: 10.1093/carcin/bgu032. [PubMed] [Cross Ref]
17. Hrasovec S, Glavac D. MicroRNAs as Novel Biomarkers in Colorectal Cancer. Front Genet. 2012;3:180. doi: 10.3389/fgene.2012.00180. [PMC free article] [PubMed] [Cross Ref]
18. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–33. doi: 10.1016/j.cell.2009.01.002. [PMC free article] [PubMed] [Cross Ref]
19. Bonfrate L, Altomare DF, Di Lena M, Travaglio E, Rotelli MT, De Luca A, Portincasa P. MicroRNA in colorectal cancer: new perspectives for diagnosis, prognosis and treatment. J Gastrointestin Liver Dis. 2013;22:311–20. [PubMed]
20. Strillacci A, Valerii MC, Sansone P, Caggiano C, Sgromo A, Vittori L, Fiorentino M, Poggioli G, Rizzello F, Campieri M, Spisni E. Loss of miR-101 expression promotes Wnt/beta-catenin signalling pathway activation and malignancy in colon cancer cells. J Pathol. 2013;229:379–89. doi: 10.1002/path.4097. [PubMed] [Cross Ref]
21. Ma Y, Zhang P, Wang F, Zhang H, Yang Y, Shi C, Xia Y, Peng J, Liu W, Yang Z, Qin H. Elevated oncofoetal miR-17-5p expression regulates colorectal cancer progression by repressing its target gene P130. Nat Commun. 2012;3:1291. doi: 10.1038/ncomms2276. [PubMed] [Cross Ref]
22. Hwang WL, Jiang JK, Yang SH, Huang TS, Lan HY, Teng HW, Yang CY, Tsai YP, Lin CH, Wang HW, Yang MH. MicroRNA-146a directs the symmetric division of Snail-dominant colorectal cancer stem cells. Nat Cell Biol. 2014;16:268–80. doi: 10.1038/ncb2910. [PubMed] [Cross Ref]
23. Hsieh IS, Chang KC, Tsai YT, Ke JY, Lu PJ, Lee KH, Yeh SD, Hong TM, Chen YL. MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway. Carcinogenesis. 2013;34:530–8. doi: 10.1093/carcin/bgs371. [PubMed] [Cross Ref]
24. Zhang N, Li X, Wu CW, Dong Y, Cai M, Mok MT, Wang H, Chen J, Ng SS, Chen M, Sung JJ, Yu J. microRNA-7 is a novel inhibitor of YY1 contributing to colorectal tumorigenesis. Oncogene. 2013;32:5078–88. doi: 10.1038/onc.2012.526. [PubMed] [Cross Ref]
25. Ji D, Chen Z, Li M, Zhan T, Yao Y, Zhang Z, Xi J, Yan L, Gu J. MicroRNA-181a promotes tumor growth and liver metastasis in colorectal cancer by targeting the tumor suppressor WIF-1. Mol Cancer. 2014;13:86. doi: 10.1186/1476-4598-13-86. [PMC free article] [PubMed] [Cross Ref]
26. Sun MM, Li JF, Guo LL, Xiao HT, Dong L, Wang F, Huang FB, Cao D, Qin T, Yin XH, Li JM, Wang SL. TGF-beta1 suppression of microRNA-450b-5p expression: a novel mechanism for blocking myogenic differentiation of rhabdomyosarcoma. Oncogene. 2014;33:2075–86. doi: 10.1038/onc.2013.165. [PubMed] [Cross Ref]
27. Jin Y, Jiang Z, Guan X, Chen Y, Tang Q, Wang G, Wang X. miR-450b-5p Suppresses Stemness and the Development of Chemoresistance by Targeting SOX2 in Colorectal Cancer. DNA Cell Biol. 2016;35:249–56. doi: 10.1089/dna.2015.3120. [PubMed] [Cross Ref]
28. Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA, Jr, Sjoblom T, Barad O, Bentwich Z, Szafranska AE, Labourier E, Raymond CK, Roberts BS, Juhl H, et al. The colorectal microRNAome. Proc Natl Acad Sci U S A. 2006;103:3687–92. doi: 10.1073/pnas.0511155103. [PubMed] [Cross Ref]
29. Lemieux E, Cagnol S, Beaudry K, Carrier J, Rivard N. Oncogenic KRAS signalling promotes the Wnt/beta-catenin pathway through LRP6 in colorectal cancer. Oncogene. 2015;34:4914–27. doi: 10.1038/onc.2014.416. [PMC free article] [PubMed] [Cross Ref]
30. Li J, Mizukami Y, Zhang X, Jo WS, Chung DC. Oncogenic K-ras stimulates Wnt signaling in colon cancer through inhibition of GSK-3beta. Gastroenterology. 2005;128:1907–18. [PubMed]
31. Liao WT, Ye YP, Zhang NJ, Li TT, Wang SY, Cui YM, Qi L, Wu P, Jiao HL, Xie YJ, Zhang C, Wang JX, Ding YQ. MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targeting KRAS, PIK3CD and BCL2. J Pathol. 2014;232:415–27. doi: 10.1002/path.4309. [PubMed] [Cross Ref]
32. Liao WT, Li TT, Wang ZG, Wang SY, He MR, Ye YP, Qi L, Cui YM, Wu P, Jiao HL, Zhang C, Xie YJ, Wang JX, et al. microRNA-224 promotes cell proliferation and tumor growth in human colorectal cancer by repressing PHLPP1 and PHLPP2. Clin Cancer Res. 2013;19:4662–72. doi: 10.1158/1078-0432.CCR-13-0244. [PubMed] [Cross Ref]
33. Zhao Z, Li R, Sha S, Wang Q, Mao W, Liu T. Targeting HER3 with miR-450b-3p suppresses breast cancer cells proliferation. Cancer Biol Ther. 2014;15:1404–12. doi: 10.4161/cbt.29923. [PMC free article] [PubMed] [Cross Ref]
34. Svoboda M, Sana J, Fabian P, Kocakova I, Gombosova J, Nekvindova J, Radova L, Vyzula R, Slaby O. MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Radiat Oncol. 2012;7:195. doi: 10.1186/1748-717X-7-195. [PMC free article] [PubMed] [Cross Ref]
35. Rohr C, Kerick M, Fischer A, Kuhn A, Kashofer K, Timmermann B, Daskalaki A, Meinel T, Drichel D, Borno ST, Nowka A, Krobitsch S, McHardy AC, et al. High-throughput miRNA and mRNA sequencing of paired colorectal normal, tumor and metastasis tissues and bioinformatic modeling of miRNA-1 therapeutic applications. PLoS One. 2013;8:e67461. doi: 10.1371/journal.pone.0067461. [PMC free article] [PubMed] [Cross Ref]
36. Reid JF, Sokolova V, Zoni E, Lampis A, Pizzamiglio S, Bertan C, Zanutto S, Perrone F, Camerini T, Gallino G, Verderio P, Leo E, Pilotti S, et al. miRNA profiling in colorectal cancer highlights miR-1 involvement in MET-dependent proliferation. Mol Cancer Res. 2012;10:504–15. doi: 10.1158/1541-7786.mcr-11-0342. [PubMed] [Cross Ref]
37. Xu Q, Li P, Chen X, Zong L, Jiang Z, Nan L, Lei J, Duan W, Zhang D, Li X, Sha H, Wu Z, Ma Q, et al. miR-221/222 induces pancreatic cancer progression through the regulation of matrix metalloproteinases. Oncotarget. 2015;6:14153–64. doi: 10.18632/oncotarget.3686. [PMC free article] [PubMed] [Cross Ref]
38. Ihle MA, Trautmann M, Kuenstlinger H, Huss S, Heydt C, Fassunke J, Wardelmann E, Bauer S, Schildhaus HU, Buettner R, Merkelbach-Bruse S. miRNA-221 and miRNA-222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumours. Mol Oncol. 2015;9:1421–33. doi: 10.1016/j.molonc.2015.03.013. [PubMed] [Cross Ref]
39. Qi J, Yu Y, Akilli Ozturk O, Holland JD, Besser D, Fritzmann J, Wulf-Goldenberg A, Eckert K, Fichtner I, Birchmeier W. New Wnt/beta-catenin target genes promote experimental metastasis and migration of colorectal cancer cells through different signals. Gut. 2015 doi: 10.1136/gutjnl-2014-307900. [PubMed] [Cross Ref]
40. Mir R, Pradhan SJ, Patil P, Mulherkar R, Galande S. Wnt/beta-catenin signaling regulated SATB1 promotes colorectal cancer tumorigenesis and progression. Oncogene. 2016;35:1679–91. doi: 10.1038/onc.2015.232. [PubMed] [Cross Ref]
41. Ayadi M, Bouygues A, Ouaret D, Ferrand N, Chouaib S, Thiery JP, Muchardt C, Sabbah M, Larsen AK. Chronic chemotherapeutic stress promotes evolution of stemness and WNT/beta-catenin signaling in colorectal cancer cells: implications for clinical use of WNT-signaling inhibitors. Oncotarget. 2015;6:18518–33. doi: 10.18632/oncotarget.3934. [PMC free article] [PubMed] [Cross Ref]
42. Knauer SK, Mahendrarajah N, Roos WP, Kramer OH. The inducible E3 ubiquitin ligases SIAH1 and SIAH2 perform critical roles in breast and prostate cancers. Cytokine Growth Factor Rev. 2015;26:405–13. doi: 10.1016/j.cytogfr.2015.04.002. [PubMed] [Cross Ref]
43. Sui C, Ma J, Chen Q, Yang Y. The variation trends of SFRP2 methylation of tissue, feces, and blood detection in colorectal cancer development. Eur J Cancer Prev. 2016;25:288–98. doi: 10.1097/CEJ.0000000000000185. [PubMed] [Cross Ref]
44. Xavier CP, Melikova M, Chuman Y, Uren A, Baljinnyam B, Rubin JS. Secreted Frizzled-related protein potentiation versus inhibition of Wnt3a/beta-catenin signaling. Cell Signal. 2014;26:94–101. doi: 10.1016/j.cellsig.2013.09.016. [PMC free article] [PubMed] [Cross Ref]
45. Silva AL, Dawson SN, Arends MJ, Guttula K, Hall N, Cameron EA, Huang TH, Brenton JD, Tavare S, Bienz M, Ibrahim AE. Boosting Wnt activity during colorectal cancer progression through selective hypermethylation of Wnt signaling antagonists. BMC Cancer. 2014;14:891. doi: 10.1186/1471-2407-14-891. [PMC free article] [PubMed] [Cross Ref]
46. Morkel M, Riemer P, Blaker H, Sers C. Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance. Oncotarget. 2015;6:20785–800. doi: 10.18632/oncotarget.4750. [PMC free article] [PubMed] [Cross Ref]
47. Vakiani E, Solit DB. KRAS and BRAF: drug targets and predictive biomarkers. J Pathol. 2011;223:219–29. doi: 10.1002/path.2796. [PubMed] [Cross Ref]
48. Pretlow TP, Pretlow TG. Mutant KRAS in aberrant crypt foci (ACF): initiation of colorectal cancer? Biochim Biophys Acta. 2005;1756:83–96. doi: 10.1016/j.bbcan.2005.06.002. [PubMed] [Cross Ref]
49. Smakman N, Borel Rinkes IH, Voest EE, Kranenburg O. Control of colorectal metastasis formation by K-Ras. Biochim Biophys Acta. 2005;1756:103–14. doi: 10.1016/j.bbcan.2005.07.001. [PubMed] [Cross Ref]
50. Pereira AA, Rego JF, Morris V, Overman MJ, Eng C, Garrett CR, Boutin AT, Ferrarotto R, Lee M, Jiang ZQ, Hoff PM, Vauthey JN, Vilar E, et al. Association between KRAS mutation and lung metastasis in advanced colorectal cancer. Br J Cancer. 2015;112:424–8. doi: 10.1038/bjc.2014.619. [PMC free article] [PubMed] [Cross Ref]
51. Pandey MK, Liu G, Cooper TK, Mulder KM. Knockdown of c-Fos suppresses the growth of human colon carcinoma cells in athymic mice. Int J Cancer. 2012;130:213–22. doi: 10.1002/ijc.25997. [PMC free article] [PubMed] [Cross Ref]
52. Mar AC, Chu CH, Lee HJ, Chien CW, Cheng JJ, Yang SH, Jiang JK, Lee TC. Interleukin-1 Receptor Type 2 Acts with c-Fos to Enhance the Expression of Interleukin-6 and Vascular Endothelial Growth Factor A in Colon Cancer Cells and Induce Angiogenesis. J Biol Chem. 2015;290:22212–24. doi: 10.1074/jbc.M115.644823. [PMC free article] [PubMed] [Cross Ref]

Articles from Oncotarget are provided here courtesy of Impact Journals, LLC